The United States Food and Drug Administration (FDA) accepted a letter of intent on Wednesday for an AI-based tool designed to predict drug-induced liver injury. This digital liver model is the first AI-driven safety tool admitted to the agency’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program. The move addresses a primary cause of clinical trial failures by improving early safety assessments before human testing begins.

Solving the Liver Toxicity Bottleneck